20.500.12556/DiRROS-12685 Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : final analysis of the GioTag study Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment >/=10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. non-small cell lung carcinoma -- therapy drug therapy afatinib osimertinib GioTag study nedrobnocelični karcinom pljuč -- terapija terapija z zdravili afatinib osimertinib raziskava GioTag true false true Future Medicine Ltd Angleški jezik Ni določen © 2020 Maximilian J. Hochmair and other authors Neznano 2020-11-18 13:29:03 2020-11-18 13:29:04 2022-08-18 03:38:49 0000-00-00 00:00:00 2020 0 Velika Britanija 0 Nasl. z nasl. zaslona; Opis vira z dne 14. 11. 2020; Soavtorica iz Slovenije: Tanja Cufer; str. [1-10] no. Vol. 16 2020 0000-00-00 Zaloznikova VTisku NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 1744-8301 10.2217/fon-2020-0740 37424899 521824025 RAZ_Hochmair_Maximilian_J_i2020.pdf RAZ_Hochmair_Maximilian_J_i2020.pdf 1 E5B817D1334C093553F6EC429C0A7178 a333a0786aedf6b7f40d2e5c6079b8fca560ff63fd584d1a640e4a9feaca69af 87ed06a3-17b6-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=17206 RAZ_Hochmair_Maximilian_J_i2020.pdf RAZ_Hochmair_Maximilian_J_i2020.pdf 1 C384BC86E3FD51111A4BAD50BC370759 2472d6292157dd65ed53ab637f6dc02f3082c3c2c4e977f6ebf36acdb13ba153 88000995-17b6-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=17207 https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0740 1 https://dirros.openscience.si/Dokument.php?lang=slv&id=15443 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0